Company news_innoModel-Provide preclinical pharmacological services

Cn /En

News Center

——

Company news

Industry news

09-03

InnoModels Biotechnology iHuPDX Platform

In the biomedical field, innovation is a key driver for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. iHuPDX platform not only demonstrates InnoModels BioTech's profound strength in the field of personalized medicine, but also provides new hopes and possibilities for tumor treatment. The iHuPDX platform not only demonstrates the profound strength of Thermo Scientific in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.

09-02

InnoModels Biotechnology Brain In Situ Model

In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. with its leading brain in-situ modeling technology, like a bright star, is gradually illuminating the future of the field of neuroscience. This technology not only provides scientists with a more realistic and complex research platform, but also greatly advances our understanding of brain function and disease mechanisms.

08-30

3D Organoid Platform of InnoModels Biotechnology

In the continuous progress of biomedical research, the authenticity and reliability of in vitro models have become the focus of scientists' attention. Although traditional cell culture technology provides important support for drug discovery and disease research, its two-dimensional environment is difficult to fully simulate the complex physiological structure and function of the human body. InnoModels Biotechnology (Beijing) Co., Ltd. provides scientists with experimental tools that are closer to the real physiological environment with its cutting-edge 3D organoid platform technology, which greatly promotes the development of biomedical research.

08-29

Introducing the InnoModels Biotechnology IC50 Cell Activity Assay Platform

The IC50 Cell Activity Assay Platform of InnoModels Biotechnology (Beijing) Co., Ltd. is a professional service platform integrating years of experience in cell culture and IC50 assay. The platform was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University, and is dedicated to providing high-quality and reliable cell activity assay services to help research and development of oncology and tumor immunotherapy.

< 1...6 7 8...61 >

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License